AccuSculpt/AccuLiftTM Laser Lipolysis System
Laser assisted liposuction is one of the many tools plastic surgeons are finding useful as demand continues for less invasive body shaping procedures. A newcomer to the market, recently receiving regulatory clearance from the FDA, the AccuSculptTM Laser Lipolysis System, according to the manufacturer, is the first Pulsed Nd:YAG Laser to deliver a 1444 nanometer(nm) wavelength. The special wavelength is said to allow for improved accuracy, precision, control and minimally-invasive deep tissue heating. For areas of the face, the AccuLift facial contouring procedure applies the AccuSculpt system with a very small cannula.
According to the manufacturer, AccuSculpt laser-lipolysis is indicated for the surgical incision, excision, vaporization, ablation, and coagulation of soft tissue. The unique wavelength provides significantly more absorption than other wavelengths. This is said to translate into much quicker fat emulsification with very low peripheral thermal damage.
Post-operative pain and swelling can occur, and burns may be possible. AccuSculpt is used on all areas of the body. The target age for patients is 20 to 70. Generally, younger, more elastic skin has greater ability to tighten or contract after subsurface volume reduction, otherwise older, less elastic skin is less able to adjust.
Many of the topics discussed in this section are procedures or technologies that are relatively new or currently under clinical investigation and may require further scientific study to determine efficacy and success rate.
These topics are presented for research and education purposes only. The ASPS does not endorse the procedures or technologies in this section.
Physicians using such procedures or technologies are advised to make individual treatment decisions according to their own medical judgment in light of each patient's individual circumstance.
Further, any reporting or publication of the information presented must be done responsibly with full disclosure of its unproven nature.